STIP1 and renal cell carcinoma: Notably, treatment with anti-STIP1 and/or anti-PrPC antibody significantly abrogates these effects in both enriched bone-seeking RCC cell line OS-RC-2-BM5 and the murine preosteoclast cell line RAW264 [151].